188 related articles for article (PubMed ID: 12487364)
1. Evaluation of Tier I screening approaches for detecting endocrine-active compounds (EACs).
O'Connor JC; Cook JC; Marty MS; Davis LG; Kaplan AM; Carney EW
Crit Rev Toxicol; 2002; 32(6):521-49. PubMed ID: 12487364
[TBL] [Abstract][Full Text] [Related]
2. Critical review and evaluation of the uterotrophic bioassay for the identification of possible estrogen agonists and antagonists: in support of the validation of the OECD uterotrophic protocols for the laboratory rodent. Organisation for Economic Co-operation and Development.
Owens JW; Ashby J
Crit Rev Toxicol; 2002; 32(6):445-520. PubMed ID: 12487363
[TBL] [Abstract][Full Text] [Related]
3. Development of a Tier I screening battery for detecting endocrine-active compounds (EACs).
Cook JC; Kaplan MA; Davis LG; O'Connor JC
Regul Toxicol Pharmacol; 1997 Aug; 26(1 Pt 1):60-8. PubMed ID: 9339481
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of a Tier I screening battery for detecting endocrine-active compounds (EACs) using the positive controls testosterone, coumestrol, progesterone, and RU486.
O'Connor JC; Davis LG; Frame SR; Cook JC
Toxicol Sci; 2000 Apr; 54(2):338-54. PubMed ID: 10774816
[TBL] [Abstract][Full Text] [Related]
5. An ongoing validation of a Tier I screening battery for detecting endocrine-active compounds (EACs).
O'Connor JC; Cook JC; Slone TW; Makovec GT; Frame SR; Davis LG
Toxicol Sci; 1998 Nov; 46(1):45-60. PubMed ID: 9928668
[TBL] [Abstract][Full Text] [Related]
6. Sensitivity of a Tier I screening battery compared to an in utero exposure for detecting the estrogen receptor agonist 17 beta-estradiol.
O'Connor JC; Frame SR; Biegel LB; Cook JC; Davis LG
Toxicol Sci; 1998 Aug; 44(2):169-84. PubMed ID: 9742655
[TBL] [Abstract][Full Text] [Related]
7. Detection of dopaminergic modulators in a tier I screening battery for identifying endocrine-active compounds (EACs).
O'Connor JC; Davis LG; Frame SR; Cook JC
Reprod Toxicol; 2000; 14(3):193-205. PubMed ID: 10838120
[TBL] [Abstract][Full Text] [Related]
8. Uncertainties for endocrine disrupters: our view on progress.
Daston GP; Cook JC; Kavlock RJ
Toxicol Sci; 2003 Aug; 74(2):245-52. PubMed ID: 12730617
[TBL] [Abstract][Full Text] [Related]
9. Key learnings from performance of the U.S. EPA Endocrine Disruptor Screening Program (EDSP) Tier 1 in vitro assays.
LeBaron MJ; Coady KK; O'Connor JC; Nabb DL; Markell LK; Snajdr S; Sue Marty M
Birth Defects Res B Dev Reprod Toxicol; 2014 Feb; 101(1):23-42. PubMed ID: 24515815
[TBL] [Abstract][Full Text] [Related]
10. Application of an integrated testing strategy to the U.S. EPA endocrine disruptor screening program.
Willett CE; Bishop PL; Sullivan KM
Toxicol Sci; 2011 Sep; 123(1):15-25. PubMed ID: 21642633
[TBL] [Abstract][Full Text] [Related]
11. In vitro models in endocrine disruptor screening.
Charles GD
ILAR J; 2004; 45(4):494-501. PubMed ID: 15454688
[TBL] [Abstract][Full Text] [Related]
12. Key lessons from performance of the U.S. EPA Endocrine Disruptor Screening Program (EDSP) Tier 1 male and female pubertal assays.
Stump DG; O'Connor JC; Lewis JM; Marty MS
Birth Defects Res B Dev Reprod Toxicol; 2014 Feb; 101(1):43-62. PubMed ID: 24510766
[TBL] [Abstract][Full Text] [Related]
13. Use of the laboratory rat as a model in endocrine disruptor screening and testing.
Gray LE; Wilson V; Noriega N; Lambright C; Furr J; Stoker TE; Laws SC; Goldman J; Cooper RL; Foster PM
ILAR J; 2004; 45(4):425-37. PubMed ID: 15454681
[TBL] [Abstract][Full Text] [Related]
14. Cross-species conservation of endocrine pathways: a critical analysis of tier 1 fish and rat screening assays with 12 model chemicals.
Ankley GT; Gray LE
Environ Toxicol Chem; 2013 Apr; 32(5):1084-7. PubMed ID: 23401061
[TBL] [Abstract][Full Text] [Related]
15. Xenoendocrine disrupters-tiered screening and testing: filling key data gaps.
Gray LE; Ostby J; Wilson V; Lambright C; Bobseine K; Hartig P; Hotchkiss A; Wolf C; Furr J; Price M; Parks L; Cooper RL; Stoker TE; Laws SC; Degitz SJ; Jensen KM; Kahl MD; Korte JJ; Makynen EA; Tietge JE; Ankley GT
Toxicology; 2002 Dec; 181-182():371-82. PubMed ID: 12505339
[TBL] [Abstract][Full Text] [Related]
16. Key learnings from the Endocrine Disruptor Screening Program (EDSP) Tier 1 rodent uterotrophic and Hershberger assays.
Marty MS; O'Connor JC
Birth Defects Res B Dev Reprod Toxicol; 2014 Feb; 101(1):63-79. PubMed ID: 24515841
[TBL] [Abstract][Full Text] [Related]
17. Answering the endocrine test questions.
Schmidt CW
Environ Health Perspect; 1999 Sep; 107(9):A458-60. PubMed ID: 10464085
[TBL] [Abstract][Full Text] [Related]
18. Toxicogenomic approach to endocrine disrupters: identification of a transcript profile characteristic of chemicals with estrogenic activity.
Naciff JM; Daston GP
Toxicol Pathol; 2004; 32 Suppl 2():59-70. PubMed ID: 15503665
[TBL] [Abstract][Full Text] [Related]
19. Endocrine-disrupting chemicals: prepubertal exposures and effects on sexual maturation and thyroid function in the male rat. A focus on the EDSTAC recommendations. Endocrine Disrupter Screening and Testing Advisory Committee.
Stoker TE; Parks LG; Gray LE; Cooper RL
Crit Rev Toxicol; 2000 Mar; 30(2):197-252. PubMed ID: 10759431
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of EPA's Tier 1 Endocrine Screening Battery and recommendations for improving the interpretation of screening results.
Borgert CJ; Mihaich EM; Quill TF; Marty MS; Levine SL; Becker RA
Regul Toxicol Pharmacol; 2011 Apr; 59(3):397-411. PubMed ID: 21251942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
